ArticleNature medicine2023
Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging.
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 3 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- The Performance of Artificial Intelligence in Classifying Molecular Markers in Adult-Type Gliomas Using Histopathological Images: Systematic Review.Journal of medical Internet research · 2026Pooled it
- Illuminating glioma surgery: A meta-analysis of Raman spectroscopy for intraoperative decision-making.Neurosurgical review · 2025Pooled it
- Artificial Intelligence Performance in Image-Based Cancer Identification: Umbrella Review of Systematic Reviews.Journal of medical Internet research · 2025Pooled it
- Optical microscopy predictions of focal recurrence in glioblastoma.Science advances · 2026Article
- Shining a light on brain tumors: a review of Raman spectroscopy in the operating room.Journal of biomedical optics · 2026Review
- Applications of Artificial Intelligence in Cancer Diagnosis and Treatment.Cancer medicine · 2026Review
- Translating genome-wide association studies at multiple scales: Drug target prioritization, cellular architectures, and organ imaging.Cell genomics · 2026Review
- Intraoperative technological advances and new frontiers in precision glioma surgery.Journal of neuro-oncology · 2026Review
- Advancing precision risk stratification in adult diffuse gliomas through DSC-MRI-based habitat analysis.BMC medical imaging · 2026Article
- AI-Assisted Coherent Raman Scattering Microscopy for Clinical Translation.Chemical & biomedical imaging · 2026Review
- Integrated CT-PET radiogenomics and graph-based multi-task learning for preoperative prediction of key glioma molecular markers.Neuroradiology · 2026Article
- Inhibition of EIF2S1 expression regulates the PI3K/AKT pathway to mediate apoptosis in glioma cells: an in vitro study.Neurogenetics · 2026Article
- A Comprehensive Review of Artificial Intelligence for Brain Tumor Analysis: Taxonomy, Robustness, and Open Challenges in Neuro-Oncology.Journal of imaging · 2026Review
- Neurosurgical Application of Artificial Intelligence in Pediatric Neuro-Oncology.Journal of Korean Neurosurgical Society · 2026Article
- What's new in digital and computational pathology 2026: advances in adoption, standards, AI technologies, and clinical integration.Journal of pathology and translational medicine · 2026Article
- Qualitative and quantitative assessment ofBiomedical optics express · 2026Article
- AI-driven label-free Raman spectromics for intraoperative spinal tumor assessment.NPJ digital medicine · 2026Article
- AI-Based Methods in Neuropathology for Diagnosis and Treatment of Brain Tumors.European journal of neurology · 2026Review
- New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication.World journal of surgical oncology · 2026Review
- Integrating multiomics data using a correlation based graph attention network for subtype classification in lower grade glioma.Discover oncology · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 6 institutions in 3 countries.
Funding
Abstract
Molecular classification has transformed the management of brain tumors by enabling more accurate prognostication and personalized treatment. However, timely molecular diagnostic testing for patients with brain tumors is limited, complicating surgical and adjuvant treatment and obstructing clinical trial enrollment. In this study, we developed DeepGlioma, a rapid (<90 seconds), artificial-intelligence-based diagnostic screening system to streamline the molecular diagnosis of diffuse gliomas. DeepGlioma is trained using a multimodal dataset that includes stimulated Raman histology (SRH); a rapid, label-free, non-consumptive, optical imaging method; and large-scale, public genomic data. In a prospective, multicenter, international testing cohort of patients with diffuse glioma (n = 153) who underwent real-time SRH imaging, we demonstrate that DeepGlioma can predict the molecular alterations used by the World Health Organization to define the adult-type diffuse glioma taxonomy (IDH mutation, 1p19q co-deletion and ATRX mutation), achieving a mean molecular classification accuracy of 93.3 ± 1.6%. Our results represent how artificial intelligence and optical histology can be used to provide a rapid and scalable adjunct to wet lab methods for the molecular screening of patients with diffuse glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.